Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Parallel-group, Double-blind, Placebo Controlled, Multi-center Study to Assess the Efficacy and Safety of Different Doses of BAY1002670 in Subjects With Uterine Fibroids Over 3 Months

Trial Profile

A Randomized, Parallel-group, Double-blind, Placebo Controlled, Multi-center Study to Assess the Efficacy and Safety of Different Doses of BAY1002670 in Subjects With Uterine Fibroids Over 3 Months

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 04 Jul 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vilaprisan (Primary)
  • Indications Uterine leiomyoma
  • Focus Therapeutic Use
  • Acronyms ASTEROID 1
  • Sponsors Bayer
  • Most Recent Events

    • 06 Dec 2018 Results published in the Fertility and Sterility
    • 10 Oct 2018 Results of an integrated analysis of ASTEROID 1 and 2 studies aimed to assess the efficacy and safety of vilaprisan in women with uterine fibroids using an extended patient dataset, presented at the American Society for Reproductive Medicine Scientific Congress 2018
    • 10 Oct 2018 Results of a subgroup analysis presented at the American Society for Reproductive Medicine Scientific Congress 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top